Nasopharyngeal carcinoma,Tears and blood,nasal obstruction,headache,diplopia
Conditions
Interventions
Two dose gradients (2-CTV) group:NA
3 dose gradients (3-CTV) group:NA
Sponsors
Southern Medical University Southern Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.From 2017 to 2020, patients with any T, N1-3 and M0 nasopharyngeal carcinoma were diagnosed in Nanfang Hospital; 2.Patients receiving intensity modulated radiotherapy (IMRT) concurrent chemoradiotherapy; 3.No previous history of cervical lymph node surgery, radiotherapy and chemotherapy;
Exclusion criteria
Exclusion criteria: 1.Patients with nasopharyngeal carcinoma with distant metastasis; 2.Patients with nasopharyngeal carcinoma treated with radiotherapy alone; 3.Nasopharyngeal carcinoma patients receiving radiotherapy other than intensity modulated radiotherapy (IMRT); 4.Previous history of cervical lymph node surgery, radiotherapy and chemotherapy; 5.No efficacy evaluation or loss of follow-up; 6.Patients who were judged by the researchers to be unsuitable for participating in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2 year regional relapse-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;2 year overall survival;Toxic reaction to radiotherapy; | — |
Countries
China
Contacts
Public ContactBei Chen
Southern Medical University Southern Hospital
Outcome results
None listed